Background/Aims: A successful screening colonoscopy is closely linked to the quality of a bowel preparation. In this study, we aimed to determine the impact of a 1-day clear liquid diet (CLD) compared to a 3-day combined diet (CMD) accompanied by a split-dose regimen of polyethylene glycol and electrolyte lavage solution (PEG-ELS) for screening colonoscopy. Materials and Methods: This was a prospective, randomized, endoscopist-blinded study. Patients referred for screening colonoscopy were randomized to four groups as a 1-day CLD+PEG-ELS vs. a 1-day CLD+sulfate free (SF)-PEG-ELS and a 3-day CMD+PEG-ELS vs. a 3-day CMD+SF-PEG-ELS. An assessment of the quality of colon cleaning, tolerability to the preparation, and symptoms related to the preparation were recorded. Results: A total of 506 patients were enrolled in this study. The quality of bowel preparation was significantly inferior in the CMD+PEG-ELS group than CLD+PEG-ELS (p=0.004) and CMD+SF-PEG-ELS groups (p=0.007). There were no statistical differences among the groups in terms of the polyp detection rate. With respect to an easy rating of diet following and the consumption of laxative, there were no significant differences among the four groups. Gastric fullness and nausea/vomiting were pointed out much more, especially in the SF-PEG-ELS users (p=0.008 and p=0.004, respectively). Conclusion: A 1-day CLD was not inferior to a 3-day CMD for colonoscopy preparation in terms of bowel cleaning, the polyp detection rate, and patient tolerance.
Background/Objectives: Therapeutic options for metastatic breast cancer vary according to hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, and, importantly, the newly recognized HER2-low status. In triple-negative breast cancer (TNBC), characterized by the absence of HR and HER2 receptors, therapeutic approaches and survival rates differ significantly. Current treatments have improved survival rates in metastatic diseases, resulting in an increased demand for secondary biopsies. The findings from these biopsies affect the range of therapeutic options. Methods: The data of 172 patients with metastatic breast cancer were retrospectively analyzed. The initial and subsequent biopsy specimens from these patients were compared. Their effects on survival and prognosis were analyzed statistically. Results: Overall, 12.8% of patients transitioned to triple-negative status. Upon analysis of HER2-low status, 13.4% of patients initially classified as HER2-negative transitioned to HER2-low status. The median overall survival was 26 months (95% CI: 19.1–32.8) in the HR-concordant group and 21 months (95% CI: 14.3–27.6) in the HR-discordant group (p < 0.03). Conclusions: The present study clarifies the rates of HR and HER2 receptor concordance and discordance in metastatic breast cancer. It provides a comprehensive dataset that incorporates all receptors and TNBC transformation. Furthermore, it demonstrates conversion to HER2-low status and examines the implications of TNBC transformation and HR discordance on prognosis and survival.